<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870128</url>
  </required_header>
  <id_info>
    <org_study_id>T-54/ 12.06.2009</org_study_id>
    <nct_id>NCT01870128</nct_id>
  </id_info>
  <brief_title>Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial</brief_title>
  <official_title>Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many studies have been conducted to evaluate the role of pulse steroids in early rheumatoid
      arthritis (RA) but no consensus exists. The aim of this study is to study the efficacy of
      various treatment regimens in early RA. Methods: This is a randomized open-labeled trial.
      Patients were randomised into three groups. In group A, patients were treated with single
      drug (methotrexate 15 mg/wk). The patients in Group B were treated with a combination of
      DMARDS (Methotrexate, sulfasalazine and hydroxychloroquine). The patients in Group C received
      combination therapy as in group B and 3 pulses of methylprednisolone intravenously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many studies have been conducted to evaluate the role of pulse steroids in early rheumatoid
      arthritis (RA) but no consensus exists. The aim of this study is to study the efficacy of
      various treatment regimens in early RA. Patients were divided into three groups. In group A,
      patients were treated with single drug (methotrexate 15 mg/wk). The patients in Group B were
      treated with a combination of DMARDS (Methotrexate, sulfasalazine and hydroxychloroquine).
      The patients in Group C received combination therapy as in group B and 3 pulses of
      methylprednisolone intravenously.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>22 months</time_frame>
    <description>To compare the response (EULAR criteria) to treatment in the three treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity score (DAS28)</measure>
    <time_frame>22 months</time_frame>
    <description>To compare the disease activity score (DAS28) score and its defining variables (tender joint count, swollen joint count, erythrocyte sedimentation rate and patient global assessment on visual analogue scale).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single agent Methotrexate 15 to 25 mg PO per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Steroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day Methylprednisolone 1000 mg intravenous per day for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Steroid</intervention_name>
    <description>Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day</description>
    <arm_group_label>Combination Steroid</arm_group_label>
    <other_name>Methylprednisolone 1000 mg intravenous for 3 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate 15 to 25 mg PO per week</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <other_name>Methotrexate 15 to 25 mg PO per week</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination</intervention_name>
    <description>Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day</description>
    <arm_group_label>Combination</arm_group_label>
    <other_name>Methotrexate 15 to 25 mg PO per week</other_name>
    <other_name>Hydroxychloroquine 200 mg Twice daily</other_name>
    <other_name>Sulfasalazine 2000 to 3000 mg per day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Rheumatoid Arthritis diagnosed on the basis of revised American college of
             rheumatology criteria,1987

          2. Age &gt;18 years

          3. Early Rheumatoid Arthritis i.e. less than 2 years duration

          4. Patient giving consent to participate in study

          5. Disease Modifying Anti-Rheumatic Drugs naive -

        Exclusion Criteria:

          1. Pregnant and lactating patient or planning to conceive in next year

          2. Patient who had joint surgery in last 6 months

          3. Co morbidities such as liver disease, kidney disease, hematological malignancies

          4. Uncontrolled hypertension, diabetes mellitus

          5. Coronary artery disease -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ATUL BATRA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIIMS</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>Atul Batra</investigator_full_name>
    <investigator_title>Senio Resident</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

